Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindMaze Therapeutics HoldingXSWX:MMTX +3.67%4 Debt-to-Equity is 0.05 as of Dec. 2025, which is at its 10-year median of 0.05. GuruFocus rates XSWX:MMTX with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, MindMaze Therapeutics Holding ranks better than 72.05% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MindMaze Therapeutics Holding's Debt-to-Equity or its related term are showing as below:
XSWX:MMTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.05 Max: 0.05
Current: 0.05
During the past 2 years, the highest Debt-to-Equity Ratio of MindMaze Therapeutics Holding was 0.05. The lowest was 0.05. And the median was 0.05.
XSWX:MMTX's Debt-to-Equity is ranked better than 72.05% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs XSWX:MMTX: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MindMaze Therapeutics Holding Debt-to-Equity Related Terms
MindMaze Therapeutics Holding Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:MMTX vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding (XSWX:MMTX) has a Debt-to-Equity of 0.05 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MindMaze Therapeutics Holding and its competitors. This is near median its historical median of 0.05. Over the past decade, MindMaze Therapeutics Holding's Debt-to-Equity has ranged from 0.05 to 0.05. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #270 out of 966 companies in the Biotechnology industry, placing it in the top 28%.
Is MindMaze Therapeutics Holding's Debt-to-Equity too high?
MindMaze Therapeutics Holding's current Debt-to-Equity of 0.05 is near median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.05. The Biotechnology industry median Debt-to-Equity is 0.16. MindMaze Therapeutics Holding's value of 0.05 is 68.8% below this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #270 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #270 out of 966 companies for Debt-to-Equity. This puts MindMaze Therapeutics Holding in the upper half of its industry. The industry median Debt-to-Equity is 0.16. MindMaze Therapeutics Holding's value of 0.05 is 68.8% below this benchmark. Historically, MindMaze Therapeutics Holding's own Debt-to-Equity has ranged from 0.05 to 0.05 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.16, MindMaze Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Debt-to-Equity is 0.05, which is near median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Debt-to-Equity of 0.05. The current Debt-to-Equity is 0.05, which is near median its 10-year median of 0.05 and 68.8% below the Biotechnology industry median of 0.16. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Debt-to-Equity is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
